The association between erectile dysfunction (ED) and acute myocardial infarction (AMI) among men was examined in the Integrated Healthcare Information Services National Managed Care Benchmark Database (IHCIS). The IHCIS is a fully de-identified, HIPAA-compliant database and includes complete medical history for more than 17 million managed care lives; data from more than 30 US health plans, covering seven census regions; and patient demographics, including morbidity, age and gender. A total of 12 825 ED patients and an equal number of male patients without ED were included in the retrospective cohort study. Logistic regression analyses were performed to assess the adjusted risk of AMI that accounted for age at ED diagnosis, smoking, obesity and medications including ACE inhibitors, beta blockers and statins. The cohort of men with ED were observed to have a two-fold increase in the risk for AMI (OR ¼ 1.99, 95% CI ¼ 1.17, 3.38) after adjusting for age at ED diagnosis, smoking, obesity, and use of ACE inhibitors, beta blockers and statins. Some evidence of a possible trend toward increased risk was detected by age group. After controlling for the aforementioned covariates and compared to men 30-39 y of age, it was noted that patients 40-44 y of age were 3.8 times more likely to develop an AMI (OR ¼ 3.76, 95% CI ¼ 1.21, 11.7), 45-to 49-y-old men were also more than three times as likely to have an AMI (OR ¼ 3.14, 95% CI ¼ 1.03, 9.64), and 50-to 55-y-old patients had a four-fold increased risk of developing AMI (OR ¼ 4.04, 95% CI ¼ 1.39, 11.7). The risk becomes more pronounced with increasing age, indicating the need for cardiologists and internists to monitor ED patients who may not necessarily present with cardiovascular symptoms.
Introduction
Erectile dysfunction (ED) has a multifactorial etiology 1 and manifests as organic vascular disease. Endothelial cell dysfunction has been the link between ED and cardiovascular disease (CVD). [2] [3] [4] [5] Indeed, endothelial dysfunction leads to failure of smooth muscles lining the arterioles to relax, thereby preventing vasodilation and resulting in the inability to achieve penile erection. Impaired lipid metabolism can cause cavernous smooth muscle degeneration and ED. 5, 6 Such endothelial dysfunction may also lead to the development of atherosclerosis and coronary artery disease.
ED is a condition frequently affecting men with underlying vascular disease. 2, 5, 6 There is considerable evidence to indicate that ED can be an early indicator of CVD and is a comorbid condition for coronary heart disease, 3, [5] [6] [7] [8] [9] [10] but it is unclear if ED per se can cause CVD. ED and CVD have common risk factors that include age, hypertension, diabetes, hyperlipidemia and smoking.
2-4,6-8,10-12 These risk factors adversely affect the nitric oxide (NO) activity in penile and vascular structure, and thus NO activity has been proposed as a common mechanism for ED and CVD. 13 Studies have shown that patients seeking treatment for ED had undiagnosed hypertension, 8, 14 and ischemic heart disease. 8 ED has been noticed among those with myocardial infarction, hypertension, 7, 12, 15, 16 and other cardiac diseases. 5, 8, 12 ED has been regarded as a marker for disease progression for CVD. 6, 7 Severity of ED has been shown to correspond to the severity of heart disease. 6, 17 Atherosclerosis is the primary cause of ED in about half of all ED cases among men over 50 y of age. 1, 9 This has led to the postulation that narrower blood vessels in the penis may be more prone to atherosclerosis and blockage than the coronary vessels. 7 High cholesterol and triglyceride levels could alter the endothelial function and disrupt the normal vasodilation of the penile vasculature, 2, 18 thus increasing the probability of ED. Low serum high-density lipoprotein levels have also been shown to increase the likelihood of ED. 12, 18 The central aim of this study is to examine whether ED is a predictor of acute myocardial infarction (AMI) after controlling for potential confounding variables.
Materials and methods
The Integrated Healthcare Information Services National Managed Care Benchmark Database (IHCIS) was used to conduct a retrospective cohort study. The IHCIS is a fully de-identified, HIPAAcompliant database and includes complete medical history for more than 17 million managed care lives; data from more than 30 US health plans, covering seven census regions; and patient demographics, including morbidity, age and gender. The study population consisted of patients diagnosed with ED (ICD-9 codes 302.72 and 607.84), and a comparison group of male patients without any ED diagnoses who were identified during the same year as ED patients. Cohort ntry criteria included at least one diagnosis of ED based on ICD-9 codes. Patients were from 18 to 55 y of age, 'active' in the IHCIS database for at least 6 months prior to the first ED ICD-9 diagnosis, and had to have a relatively good health status. Thus, men with a history of CVD (ischemic heart disease, ICD-9 codes 410-414; angina, ICD-9 code 413.9; transient ischemic attack, ICD-9 code 435.9; and ischemic stroke, ICD-9 code 436), diabetes mellitus (ICD-9 code 250.0), spinal cord injury (ICD-9 code 344.1) and/or any history of cancer (ICD-9 codes 140.0-199.1) were excluded from the cohort.
Each patient was followed from the date of first ED diagnosis until the first diagnosis of AMI (ICD-9 code 410), or in the absence of an AMI, a patient was censored on the last date recorded in the database. Overall, the cohort was observed between January 1, 1997 and March 31, 2002.
Baseline characteristics for the ED cohort and comparison group were described in the form of means and frequencies, and included age at ED diagnosis, smoking, obesity, and use of ACE inhibitors, beta blockers and statins.
In order to assess the effect of an ED diagnosis during middle age, logistic regression models were used to compute odds ratios for AMI after adjusting for age at ED diagnosis, smoking, obesity and medication use.
All statistical analyses were performed using SAS s statistical software (SAS Institute, Cary, NC, USA).
Results
As seen in Table 1 , the mean age of ED patients was 43. 9 y compared to a mean age of 37.2 y among patients without ED. A slightly higher percentage of ED patients were smokers (0.009%), while 0.004% of patients without ED were identified as smokers. More patients with ED were diagnosed with obesity than in the comparison group (0.04 vs 0.02%), but again the percentages were very similar. The frequency of antihypertensive and statin users was essentially the same in the two groups, although slightly greater among patients not diagnosed with ED. The percentage of men without ED on ACE inhibitors was 0.03% compared to 0.01% of men with ED. Among patients without ED, 0.03% were prescribed beta blockers, while 0.02% of ED patients were prescribed beta blockers. The percentage of men without ED on statins was 0.05% vs 0.04% of men diagnosed with ED.
The aim of the analyses was to determine whether ED was a predictor of AMI. Table 2 illustrates that there was a two-fold increase in the risk of AMI among men with ED (OR ¼ 1.99, 95% CI ¼ 1.17, 3.38), after adjusting for the following variables Although no specific test for trend was conducted, Table 3 illustrates an increased risk of AMI with increasing age, after controlling for ED diagnosis, smoking, obesity and use of medications. Compared to men 30-39 y of age, it was noted that patients 40-44 y of age were 3.8 times more likely to develop an AMI (OR ¼ 3.76, 95% CI ¼ 1.21, 11.7); 45-to 49-yold men were also more than three times as likely to have an AMI (OR ¼ 3.14, 95% CI ¼ 1.03, 9.64); and 50-to 55-y-old patients had a four-fold increased risk of developing AMI (OR ¼ 4.04, 95% CI ¼ 1.39, 11.7).
Discussion
A few studies have illustrated that ED may serve as a marker for CVD progression. 6, 7 Our study contributes to the previous literature by confirming earlier results in a claims database with a very large ED patient population. Moreover, we specifically identified a two-fold increase in the risk for AMI among men diagnosed with ED. Considering that the average follow-up period in this study was 1 y, the results are even more impressive in that we could identify 72 cases of AMI in a relatively short period of time. The study data demonstrate a general increase in the risk for AMI as age increased as well. This reaffirms the need for early intervention by identifying middle-aged men with ED who may be at risk for AMI. Indeed, many of these men may already have underlying CVD. At the same time, however, it is essential to diagnose men with ED. Given the stigma surrounding the condition, many men may feel less willing to report ED, particularly those with milder symptoms. Yet the population with mild ED may also be at high risk for AMI as the more severe cases.
The use of a large administrative database does have some limitations. The IHCIS database represents patients who have sought treatment for ED and AMI, and this often includes the more severe cases.
While men with a history of CVD and diabetes were excluded from the cohort, there could have been a percentage of patients with undetected comorbidities. However, we are not aware of any evidence that can confirm this occurrence. In addition, the sensitivity of the diagnosis of ED is not known. Therefore, there may be misclassification of true ED patients not having the condition. Such misclassification could potentially diminish the positive relationship that was observed.
CVD affects more than 61 million people in the United States, and is predicted to remain the highest-ranked cause of death worldwide through 2020. 19, 20 In 2002, the annual number of American men 29-44 y of age having diagnosed new or recurrent heart attack was 34 000. 20 But there were 257 000 new or recurrent heart attacks among American men 45-64 y of age, 20 and 430 000 new or recurrent heart attacks among American men aged 65 and older. 20 Again, early detection of ED may prevent the occurrence of AMI. Inarguably, the development of therapeutic agents and surgical procedures has helped to prevent, treat and reduce the risk of mortality from AMI. Nevertheless, health care utilization costs continue to increase. 21 The application of cost-effective analyses will likely identify which form of prevention or treatment may provide optimal benefits clinically and economically for ED patients. a The models are adjusted for ED diagnosis, smoking, obesity, and use of ACE inhibitors, beta blockers and statins.
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